Company intelligence / Profile preview

M-Tubulin

Ownership: Private
Development stage: Other

Overview

M-Tubulin is a biotechnology company focused on the development of novel small molecule therapeutics targeting tubulin for the treatment of cancer. The company's lead research centers on overcoming resistance to traditional microtubule-targeting agents by developing compounds that bind to specific sites on the tubulin protein. Their approach aims to provide more effective and less toxic treatment options for patients with various solid tumors. M-Tubulin is currently in the pre-clinical stage of development, advancing its pipeline through rigorous laboratory and animal studies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on M-Tubulin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on M-Tubulin.

Explore the full profile